Zacks Investment Research Downgrades ProQR Therapeutics N.V. (PRQR) to Hold
Zacks Investment Research cut shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a buy rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
Separately, HC Wainwright reissued a buy rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of $14.15.
Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) opened at 5.30 on Tuesday. The company’s market capitalization is $127.76 million. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The firm’s 50-day moving average price is $5.02 and its 200 day moving average price is $4.88.
Several institutional investors have recently modified their holdings of the company. Sphera Funds Management LTD. increased its position in shares of ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after buying an additional 130,000 shares during the period. Artal Group S.A. increased its position in shares of ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 100,000 shares during the period. Janus Henderson Group PLC bought a new position in shares of ProQR Therapeutics N.V. during the second quarter worth about $2,028,000. Finally, Redmile Group LLC increased its position in shares of ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after buying an additional 43,050 shares during the period. Institutional investors own 35.93% of the company’s stock.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.